Tapentadol
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Tapentadol: From Moderate-to-Severe Pain to Migraine Disorder
One-Sentence Summary
Tapentadol is a centrally-acting opioid analgesic (μ-opioid agonist plus norepinephrine reuptake inhibitor) used for moderate-to-severe pain; it is not currently marketed in India. The TxGNN model predicts a possible new indication in Migraine Disorder, but this signal is currently supported by 0 clinical trials and only 2 indirectly relevant publications — neither of which studies tapentadol itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Moderate-to-severe pain (opioid analgesic class; no India-specific approved indication text available — drug not registered locally) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.67% |
| Evidence Level | L5 (model prediction only) |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from DrugBank (flagged as a High-severity data gap). Based on the repurposing rationale generated for this candidate, Tapentadol is a µ-opioid receptor agonist combined with a norepinephrine reuptake inhibitor (NRI). The NRI component theoretically overlaps with the mechanism of some SNRI-class migraine prophylactic agents, which modulate descending pain-inhibitory pathways.
However, this mechanistic overlap is weak and should not be over-interpreted. International headache society guidelines and most clinical practice guidelines explicitly recommend against using opioids for acute or preventive migraine treatment, because they lack demonstrated superiority over triptans/NSAIDs and carry a well-documented risk of medication-overuse headache (MOH) and migraine chronification. The predicted association appears to be driven primarily by network-level similarity in the knowledge graph rather than by a validated pharmacological or clinical rationale, and the supporting literature (below) does not mention tapentadol at all.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27096578 | 2016 | Review (Cochrane) | Cochrane Database of Systematic Reviews | Reviews dipyrone (metamizole), a non-opioid analgesic, for postoperative and migraine pain; does not evaluate tapentadol |
| 27096438 | 2016 | Review (Cochrane) | Cochrane Database of Systematic Reviews | Reviews sumatriptan plus naproxen for acute migraine attacks; does not evaluate opioids or tapentadol |
Note: Both publications discuss migraine pharmacotherapy in general but provide no direct evidence for tapentadol’s use in migraine. They are included as background context only.
India Market Information
Tapentadol has no registered product licenses in India according to the regulatory data on file (0 total licenses). No dosage form or approved indication text is available for local review.
Safety Considerations
Drug Interactions (120 total interactions on file; source: DDInter). Selected Major-severity interactions relevant to opioid/serotonergic risk:
- Bupropion — Major
- Morphine — Major (additive CNS/respiratory depression)
- Lorcaserin — Major (serotonergic risk)
- Diethylpropion — Major
- Dolasetron — Major
- Palonosetron — Major
- Phentermine — Major
Additional Moderate-level interactions include anticholinergics (Atropine, Hyoscyamine, Glycopyrronium, Dicyclomine, Trospium), Naloxone, Epinephrine, and cannabinoid-class agents (Dronabinol, Nabilone).
Key warnings and contraindications from the local package insert are not yet available (Blocking data gap — TFDA/India label not yet retrieved); these must be obtained before any safety sign-off.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a single network-derived score (L5, no clinical or drug-specific literature support), and the mechanistic argument is weak — established migraine treatment guidelines actively discourage opioid use due to MOH and chronification risk. The drug is also not currently marketed in India, and core safety documentation (label warnings/contraindications) is missing.
To proceed, the following is needed:
- Resolve Blocking gap DG001: retrieve and parse the official package insert (warnings/contraindications) before any S1 safety review
- Resolve High-severity gap DG002: confirm mechanism of action via DrugBank API
- Obtain confirmed original indication and regulatory status (approval history in source market, e.g., US/EU label)
- Targeted literature/trial search specifically for “tapentadol AND migraine” to determine if any drug-specific evidence exists beyond the network prediction
- Reassess against migraine treatment guidelines to formally document why opioid-class agents are generally not recommended, before considering further investment in this candidate
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.